

Form PTO-1449

Docket Number 421842000400

Application Number 10/627,372

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Harrihar A. PERSHADSINGH

Filing Date July 24, 2003

Group Art Unit Not Yet Assigned

Mailing Date November 21, 2003

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
100	1.	02/15/2000	RE 36,575	Meguro et al.			
	2.	07/07/1992	5,128,356	Naka et al.			
	3.	11/10/1992	5,162,326	Naka et al.			
	4.	03/23/1993	5,196,444	Naka et al.			
	5.	09/07/1993	5,243,054	Naka et al.			
	6.	10/05/1993	5,250,554	Naka et al.			
	7.	02/08/1994	5,284,661	Morimoto et al.			
	8.	07/12/1994	5,328,919	Naka et al.			
	9.	10/11/1994	5,354,766	Naka et al.			
	10.	02/14/1995	5,389,641	Naka et al.			
	11.	03/28/1995	5,401,764	Naka et al.			
	12.	10/31/1995	5,463,073	Takehiko et al.			
	13.	03/05/1996	5,496,835	Kubo et al.			
	14.	03/19/1996	5,500,427	Kubo et al.			
	15.	04/09/1996	5,506,245	Regnier et al.			
	16.	07/30/1996	5,541,229	Narr et al.			
	17.	10/15/1996	5,565,469	Mihm et al.			
	18.	12/10/1996	5,583,141	Naka et al.			
	19.	12/24/1996	5,587,393	Narr et al.			
	20.	01/07/1997	5,591,762	Hauel et al.			
	21.	01/14/1997	5,594,003	Hauel et al.			
	22.	02/11/1997	5,602,127	Hauel et al.			
	23.	03/25/1997	5,614,519	Hauel et al.			
	24.	06/17/1997	5,639,773	Kubo et al.			
	25.	09/02/1997	5,663,186	Nelson et al.			
	26.	09/02/1997	5,663,187	Nelson et al.			
111	27.	11/04/1997	5,684,029	Narr et al.			

EXAMINER:

100 - Weebote

DATE CONSIDERED:

1-28-08

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 421842000400

Application Number 10/627,372

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

Applicant


Harrihar A. PERSHADSINGH

Filing Date July 24, 2003

Group Art Unit Not Yet Assigned

Mailing Date November 21, 2003

(Use several sheets if necessary)



28.	12/02/1997	5,693,651	Nomura et al.			
29.	12/30/1997	5,703,110	Naka et al.			
30.	01/06/1998	5,705,517	Naka et al.			
31.	04/07/1998	5,736,555	Naka et al.			
32.	04/21/1998	5,741,803	Pool et al.			
33.	09/01/1998	5,801,173	Lohray et al.			
34.	09/22/1998	5,811,439	Ogawa et al.			
35.	10/06/1998	5,817,075	Giungo			
36.	10/20/1998	5,824,694	Kurtz et al.			
37.	10/27/1998	5,827,865	Haigh et al.			
38.	11/10/1998	5,834,501	Fujita et al.			
39.	12/01/1998	5,843,172	Yan			
40.	12/01/1998	5,843,970	Pershad Singh et al.			
41.	12/08/1998	5,847,008	Doebber et al.			
42.	01/12/1999	5,859,051	Adams et al.			
43.	01/26/1999	5,864,043	Narr et al.			
44.	02/09/1999	5,868,728	Giungo et al.			
45.	02/09/1999	5,869,495	Haigh et al.			
46.	03/16/1999	5,883,111	Naka et al.			
47.	03/23/1999	5,885,997	Lohray et al.			
48.	03/23/1999	5,886,014	Fujita et al.			
49.	03/30/1999	5,889,025	Lohray et al.			
50.	03/30/1999	5,889,032	Lohray et al.			
51.	05/11/1999	5,902,726	Kliwer et al.			
52.	06/08/1999	5,910,592	Pool et al.			
53.	07/06/1999	5,919,782	Lohray et al.			
54.	07/20/1999	5,925,656	Kallam et al.			
55.	08/03/1999	5,932,601	Sohda et al.			
56.	08/17/1999	5,939,442	Evans et al.			
57.	09/14/1999	5,952,356	Ikeda et al.			

EXAMINER:

W. C. W.

DATE CONSIDERED:

1-25-05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 421842000400

Application Number 10/627,372

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Harrihar A. PERSHADSINGH

Filing Date July 24, 2003

Group Art Unit Not Yet Assigned

Mailing Date November 21, 2003

58.	09/14/1999	5,952,509	Saito et al.
59.	09/28/1999	5,958,942	Takatani et al.
60.	09/28/1999	5,958,961	Inada et al.
61.	10/05/1999	5,962,470	Fujita et al.
62.	10/05/1999	5,962,491	Naka et al.
63.	10/12/1999	5,965,584	Ikeda et al.
64.	10/19/1999	5,968,589	Murakami
65.	10/26/1999	5,972,959	Yanagisawa et al.
66.	10/26/1999	5,972,970	Sohda et al.
67.	11/02/1999	5,977,365	Fujita et al.
68.	11/16/1999	5,985,884	Lohray et al.
69.	11/23/1999	5,990,139	Yano et al.
70.	12/21/1999	6,004,989	Naka et al.
71.	12/28/1999	6,008,237	Sahoo et al.
72.	01/04/2000	6,011,031	Lohray et al.
73.	01/04/2000	6,011,036	Lohray et al.
74.	02/01/2000	6,020,382	Doebber et al.
75.	02/08/2000	6,022,897	Evans et al.
76.	02/22/2000	6,028,088	Pershad Singh et al.
77.	07/11/2000	6,087,384	Matsui et al.
78.	07/11/2000	6,087,385	Pershad Singh et al.
79.	07/18/2000	6,090,836	Adams et al.
80.	07/18/2000	6,090,839	Adams et al.
81.	08/08/2000	6,100,252	Naka et al.
82.	08/08/2000	6,100,403	Saito et al.
83.	08/15/2000	6,103,742	Ikeda et al.
84.	09/05/2000	6,113,907	Khwaja et al.
85.	09/12/2000	6,117,893	Fujita et al.
86.	11/21/2000	6,150,371	Fujiwara et al.
87.	12/12/2000	6,160,000	Adams et al.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) NOV 24 2003 PATENT & TRADEMARK OFFICE	Docket Number 421842000400	Application Number 10/627,372
	Applicant Harrihar A. PERSHADSINGH	
	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned
	Mailing Date November 21, 2003	

	88.	03/13/2001	6,200,995	De La Brouse-Elwood et al.			
	89.	05/08/2001	6,228,874	Inada et al.			
	90.	05/15/2001	6,232,334	Naka et al.			
	91.	12/11/2001	6,329,415	Cirillo et al.			
	92.	12/25/2001	6,333,325	Cirillo et al.			
	93.	02/19/2002	6,348,481	Inada et al.			
	94.	03/05/2002	6,353,011	Pershad Singh			
	95.	03/12/2002	6,355,808	Naka et al.			
	96.	03/19/2002	6,358,945	Breitfelder et al.			
	97.	04/09/2002	6,369,098	Pershad Singh			
	98.	04/16/2002	6,372,773	Regan			
	99.	07/02/2002	6,414,002	Cheng et al.			
	100.	07/02/2002	6,414,008	Hauel et al.			
	101.	07/16/2002	6,420,405	Inada et al.			
	102.	08/13/2002	6,432,993	Fujita et al.			
	103.	08/13/2002	6,432,996	Tamura et al.			
	104.	09/17/2002	6,451,832	Ries et al.			
	105.	10/22/2002	6,468,996	Jeppesen et al.			
	106.	10/22/2002	6,469,039	Hauel et al.			
	107.	11/05/2002	6,476,023	Cirillo et al.			
	108.	11/12/2002	6,479,524	Priepke et al.			
u	109.	11/26/2002	6,486,188	Pedersen et al.			

	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
10/	110.	07/17/1997	WO 97/25042	WIPO				
11/	111.	08/07/1997	WO 97/28137	WIPO				
12/	112.	02/12/1998	WO 98/05331	WIPO				
13/	113.	12/23/1998	WO 98/57941	WIPO				
14/	114.	12/09/1999	WO 99/62870	WIPO				

EXAMINER: <u>u</u>	DATE CONSIDERED: <u>1-21-03</u>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 421842000400	Application Number 10/627,372
	Applicant Hamihar A. PERSHADSINGH	
	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned
	Mailing Date November 21, 2003	

115.	12/09/1999	WO 99/62871	WIPO				
116.	12/09/1999	WO 99/62872	WIPO				
117.	07/27/2000	WO 00/27832	WIPO				
118.	01/04/2001	WO 01/00603	WIPO				
119.	02/22/2001	WO 01/12612	WIPO				
120.	03/29/2001	WO 01/21602	WIPO				
121.	05/17/2001	WO 01/34094	WIPO				
122.	10/03/2002	WO 02/076177	WIPO				

Ref. No.	Title
123.	GenBank Accession No. J03258, "Cloning and Expression of Full-Length cDNA Encoding Human Vitamin D Receptor" created on January 14, 1995, located at < http://www.ncbi.nlm.nih.gov > last visited on September 24, 2003.
124.	GenBank Accession No. L02932, "cDNA Cloning, Chromosomal Mapping, and Functional Characterization of the Human Peroxisome Proliferator Activated Receptor" created on July 26, 1993, located at < http://www.ncbi.nlm.nih.gov > last visited on September 24, 2003.
125.	GenBank Accession No. L13740, "Isolation and Characterization of Human TR3 Receptor: A Member of Steroid Receptor Superfamily" created on June 12, 1993, located at < http://www.ncbi.nlm.nih.gov > last visited on September 24, 2003.
126.	GenBank Accession No. L14160, "The Development of Sequence-Tagged Sites for Human Chromosome 4" created on August 10, 1993, located at < http://www.ncbi.nlm.nih.gov > last visited on September 24, 2003.
127.	GenBank Accession No. L14611, "Identification of Nuclear Receptor mRNAs by RT-PCR Amplification of Conserved Zinc-Finger Motif Sequences" created on October 16, 1993, located at < http://www.ncbi.nlm.nih.gov > last visited on September 24, 2003.
128.	GenBank Accession No. L27586, "Human and Rat TR4 Orphan Receptors Specify a Subclass of the Steroid Receptor Superfamily" created on September 15, 1994, located at < http://www.ncbi.nlm.nih.gov > last visited on September 24, 2003.
129.	GenBank Accession No. L31785, "A New Orphan Member of the Nuclear Hormone Receptor Superfamily Closely Related to Rev-Erb" created on May 8, 1995, located at < http://www.ncbi.nlm.nih.gov > last visited on September 24, 2003.
130.	GenBank Accession No. L40904, "Isolation of the Human Peroxisome Proliferator Activated Receptor Gamma cDNA: Expression in Hematopoietic Cells and Chromosomal Mapping" created on December 26, 2001, located at < http://www.ncbi.nlm.nih.gov > last visited on September 24, 2003.

EXAMINER: 	DATE CONSIDERED: 1-25-05
---	--------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) 		Applicant Harrihar A. PERSHADSINGH	
		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned
		Mailing Date November 21, 2003	
131.	GenBank Accession No. M24748, "Characterization of a Third Human Thyroid Hormone Receptor Coexpressed with Other Thyroid Hormone Receptors in Several Tissues" created on May 9, 1995, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
132.	GenBank Accession No. M24857, "A Third Human Retinoic Acid Receptor, hRAR-gamma" created on November 8, 1994, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
133.	GenBank Accession No. M24898, "Two erbA Homologs Encoding Proteins with Different T3 Binding Capacities are Transcribed from Opposite DNA Strands of the Same Genetic Locus" created on November 7, 1994, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
134.	GenBank Accession No. M26747, "Human Steroid Receptors and erbA Proto-Oncogene Products: Members of a New Superfamily of Enhancer Binding Proteins" created on June 11, 2002, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
135.	GenBank Accession No. M29960, "Molecular Cloning of New Human TR2 Receptors: A Class of Steroid Receptor with Multiple Ligand-Binding Domains" created on August 3, 1993, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
136.	GenBank Accession No. M64497, "Regulation of the Apolipoprotein AI Gene by ARP-1, a Novel Member of the Steroid Receptor Superfamily" created on January 31, 1996, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
137.	GenBank Accession No. M81385, "Expression and Functional Analysis of Liver Receptor Homologue-1 as a Potential Steroidogenic Factor in Rat Ovary" created on July 22, 2003, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
138.	GenBank Accession No. M84820, "Purification, Cloning, and RXR Identity of the HeLa Cell Factor with which RAR or TR Heterodimerizes to Bind Target Sequences Efficiently" created on January 9, 1995, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
139.	GenBank Accession No. S65876, "Characterization of the Mouse FTZ-F1 Gene, which Encodes a Key Regulator of Steroid Hydroxylase Gene Expression" created on May 8, 2002, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
140.	GenBank Accession No. S77482, "The Mouse Homolog of the Orphan Nuclear Receptor Tailless is Expressed in the Developing Forebrain" created on September 27, 1995, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
141.	GenBank Accession No. U10375, "Differential Expression and Activation of a Family of Murine Peroxisome Proliferator-Activated Receptors" created on July 22, 1994, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
142.	GenBank Accession No. U11551, "A Novel Bacillus Associated with Diseased Fish" created on July 19, 1994, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
143.	GenBank Accession No. U12767, "The Isolation and Characterization of MINOR, a Novel Mitogen-Inducible Nuclear Orphan Receptor" created on June 17, 1996, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
EXAMINER: 		DATE CONSIDERED: 1-21-05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/08 (2-92) pa- 820933		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Harrihar A. PERSHADSINGH	
		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned
		Mailing Date November 21, 2003	
144.	GenBank Accession No. U14534, "Ubiquitous Receptor: A Novel Receptor That Modulates Gene Activation by Retinoic Acid and Thyroid Hormone Receptors" created on January 2, 1995, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
145.	GenBank Accession No. U14666, "Cloning of a Novel Orphan Receptor (GCNF) Expressed During Germ Cell Development" created on March 23, 1996, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
146.	GenBank Accession No. U16997, "ROR Gamma: The Third Member of ROR/RZR Orphan Receptor Subfamily that is Highly Expressed in Skeletal Muscle" created on April 4, 1995, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
147.	GenBank Accession No. U18374, "Identification of a Nuclear Receptor that is Activated by Farnesol Metabolites" created on June 21, 1995, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
148.	GenBank Accession No. U38480, "Characterization of Three RXR Genes that Mediate the Action of 9-cis Retinoic Acid" created on November 8, 1995, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
149.	GenBank Accession No. X06614, "A Transferable Silencing Domain is Present in the Thyroid Hormone Receptor, in the v-erbA Oncogene Product and in the Retinoic Acid Receptor" created on September 12, 1993, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
150.	GenBank Accession No. X12794, "Identification of Two Novel Members of erbA Superfamily by Molecular Cloning: The Gene Products of the Two are Highly Related to Each Other" created on June 25, 1997, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
151.	GenBank Accession No. X12795, "Identification of Two Novel Members of erbA Superfamily by Molecular Cloning: The Gene Products of the Two are Highly Related to Each Other" created on June 25, 1997, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
152.	GenBank Accession No. X51416, "Identification of a New Class of Steroid Hormone Receptors" created on April 3, 1997, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
153.	GenBank Accession No. X51417, "Identification of a New Class of Steroid Hormone Receptors" created on February 10, 1999, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
154.	GenBank Accession No. X52773, "Nuclear Receptor That Identifies a Novel Retinoic Acid Response Pathway" created on September 12, 1993, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
155.	GenBank Accession No. X75163, "A Novel Nuclear Receptor Superfamily Member in Xenopus That Associates with RXR, and Shares Extensive Sequence Similarity to the Mammalian Vitamin D3 Receptor" created on February 2, 1994, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
EXAMINER: <i>W -</i>		DATE CONSIDERED: <i>1-21-05</i>	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 820933		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) NOV 24 2003 PATENT & TRADEMARK OFFICE		Applicant Harrihar A. PERSHADSINGH	
		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned
		Mailing Date November 21, 2003	
156.	GenBank Accession No. X75918, "NOT, a Human Immediate-Early Response Gene Closely Related to the Steroid/Thyroid Hormone Receptor NAK1/TR3" created on January 6, 1995, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
157.	GenBank Accession No. X76930, "Clonign and Sequencing of cDNAs Encoding the Human Hepatocyte Nuclear Factor 4 Indicate the Presence of Two Isoforms in Human Liver" created on November 8, 1994, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
158.	GenBank Accession No. Y00291, "A Novel Steroid Thyroid Hormone Receptor-Related Gene Inappropriately Expressed in Human Hepatocellular Carcinoma" created on January 14, 1991, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
159.	GenBank Accession No. Z49826, "Human Hepatocyte Nuclear Factor 4 Isoforms Are Encoded by Distinct and Differentially Expressed Genes" created on September 6, 1999, located at <http://www.ncbi.nlm.nih.gov> last visited on September 24, 2003.		
160.	Adams, A.D. et al. (2003). "Amphipathic 3-Phenyl-7-propylbenzisoxazoles; Human PPAR γ , δ and α Agonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 13:931-935.		
161.	Alberti, K.G.M.M. and Zimmet, P.Z. (1998). "Definition, Diagonisis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation," <i>Diabet. Med.</i> 15:539-553.		
162.	Almansa, C. et al. (1996). "Diphenylpropionic Acids as New AT ₁ Selective Angiotensin II Antagonists," <i>J. Med. Chem.</i> 39:2197-2206.		
163.	Almansa, C. et al. (1997). "Synthesis and Structure-Activity Relationship of a New Series of Potent AT ₁ Selective Angiotensin II Receptor Antagonists: 5-(Biphenyl-4-ylmethyl)pyrazoles," <i>J. Med. Chem.</i> 40:547-558.		
164.	American Diabetes Association (2002). "The Prevention or Delay of Type 2 Diabetes," <i>Diabetes Care</i> 25(4):742-749.		
165.	American Medical Association. (2001). "Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)," <i>JAMA</i> 285(19):2486-2497.		
166.	American Medical Association. (2002). "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)," <i>JAMA</i> 288(23):2981-2997.		
167.	Ashton, W.T. et al. (1994). "Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT ₁ Receptor Affinity and Enhanced AT ₂ Affinity," <i>J. Med. Chem.</i> 37:2808-2824.		
168.	Atwal, K.S. et al. (1992). "Dihydropyrimidine Angiotensin II Receptor Antagonists," <i>J. Med. Chem.</i> 35:4751-4763.		
EXAMINER: <i>W. W. de la</i>		DATE CONSIDERED: 1-21-05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/08 (2-92) pa- 820933		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Harrihar A. PERSHADSINGH	
		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned
		Mailing Date November 21, 2003	
169.	Bernhart, C.A. et al. (1993). "A New Series of Imidazolones: Highly Specific and Potent Nonpeptide AT ₁ Angiotensin II Receptor Antagonists," <i>J. Med. Chem.</i> 36:3371-3380.		
170.	Bernobich, E. et al. (2002). "The Role of the Angiotensin System in Cardiac Glucose Homeostasis: Therapeutic Implications," <i>Drugs</i> 62(9):1295-1314.		
171.	Blankley, C.J. et al. (1991). "Synthesis and Structure-Activity Relationships of a Novel Series of Non-Peptide Angiotensin II Receptor Binding Inhibitors Specific for the AT ₂ Subtype," <i>J. Med. Chem.</i> 34:3248-3260.		
172.	Brasier, A.R. et al. (2000). "Angiotensin II Induces Gene Transcription Through Cell-Type-Dependent Effects on the Nuclear Factor- κ B (NF- κ B) Transcription Factor," <i>Mol. Cell. Biochem.</i> 212:155-169.		
173.	Brooks, D.A. et al. (2001). "Design and Synthesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic Acids: A New Class of Dual PPAR α / γ Agonists," <i>J. Med. Chem.</i> 44:2061-2064.		
174.	Bühlmayer, P. et al. (1991). "Nonpeptidic Angiotensin II Antagonists: Synthesis and in Vitro Activity of a Series of Novel Naphthalene and Tetrahydronaphthalene Derivatives," <i>J. Med. Chem.</i> 34:3105-3114.		
175.	Carini, D.J. et al. (1991). "Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of <i>N</i> -(Biphenylmethyl)Imidazoles as Potent, Orally Active Antihypertensives," <i>J. Med. Chem.</i> 34:2525-2547.		
176.	Cronet, P. et al. (2001). "Structure of the PPAR α and - γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family," <i>Structure</i> 9:699-706.		
177.	Dahlöf, B. et al. (2002). "Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol," <i>The Lancet</i> 359:995-1003.		
178.	Danforth, E. Jr. (2000). "Failure of Adipocyte Differentiation Causes Type II Diabetes Mellitus?" <i>Nat. Genet.</i> 26:13.		
179.	De, B. et al. (1992). "Discovery of a Novel Class of Orally Active, Non-Peptide Angiotensin II Antagonists," <i>J. Med. Chem.</i> 35:3714-3717.		
180.	Dhanao, D.S. et al. (1993). "(Dipropylphenoxy)phenylacetic Acids: A New Generation of Nonpeptide Angiotensin II Receptor Antagonists," <i>J. Med. Chem.</i> 36:3738-3742.		
181.	Easthope, S.E. and Jarvis, B. (2002). "Candesartan Cilexetil: An Update of its Use in Essential Hypertension," <i>Drugs</i> 62(8):1253-1287.		
182.	Ellingboe, J.W. et al. (1998). "Metabolites of the Angiotensin II Antagonist Tasosartan: The Importance of a Second Acidic Group," <i>J. Med. Chem.</i> 41:4251-4260.		
EXAMINER: <i>HC - [signature]</i>			
DATE CONSIDERED: <i>1-21-05</i>			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92)		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	
pa- 820933			

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Harrihar A. PERSHADSINGH	
		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned
		Mailing Date November 21, 2003	
183.	Epstein, M. (2002). "Angiotensin II Receptor Antagonists: Current Status" Chapter 17 <i>In Angiotensin II Receptor Antagonists</i> Epstein, M. and Brunner, H.R. eds. Hanley and Belfus, Inc.: Philadelphia, PA. pp. 257-261.		
184.	Ford, E.S. et al. (2002). "Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey," <i>JAMA</i> 287(3):356-359.		
185.	Galvin, P. et al. (1992). "A Simple Method for Quantitation of Insulin Sensitivity and Insulin Release From an Intravenous Glucose Tolerance Test," <i>Diabetic Medicine</i> 9:921-928.		
186.	Groff, J.L. et al. (1993). "Simplified Enzymatic Assay of Angiotensin-Converting Enzyme in Serum," <i>Clin. Chem.</i> 39(3):400-404.		
187.	Hansson, L. et al. (1999). "Effect of Angiotensin-Converting-Enzyme Inhibition Compared with Conventional Therapy on Cardiovascular Morbidity and Mortality in Hypertension: The Captopril Prevention Project (CAPPP) Randomised Trial," <i>The Lancet</i> 353:611-616.		
188.	Henke, B.R. et al. (1998). "N-(2-Benzoylphenyl)-L-Tyrosine PPAR γ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents," <i>J. Med. Chem.</i> 41:5020-5036.		
189.	Henriksen, E.J. et al. (2001). "Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats," <i>Hypertension</i> 38:884-890.		
190.	Horiuchi, M. et al. (2003). "Fluvastatin Enhances the Inhibitory Effects of a Selective Angiotensin II Type 1 Receptor Blocker, Valsartan, on Vascular Neointimal Formation," <i>Circulation</i> 107:106-112.		
191.	Janke, J. et al. (2002). "Mature Adipocytes Inhibit In Vitro Differentiation of Human Preadipocytes Via Angiotensin Type 1 Receptors," <i>Diabetes</i> 51:1699-1707.		
192.	Katsuki, A. et al. (2001). "Homeostasis Model Assessment Is a Reliable Indicator of Insulin Resistance During Follow-up of Patients With Type 2 Diabetes," <i>Diabetes Care</i> 24(2):362-365.		
193.	Kubo, K. et al. (1993). "Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazoles," <i>J. Med. Chem.</i> 36:1772-1784.		
194.	Laaksonen, D.E. et al. (2002). "Metabolic Syndrome and Development of Diabetes Mellitus: Application and Validation of Recently Suggested Definitions of the Metabolic Syndrome in a Prospective Cohort Study," <i>American Journal of Epidemiology</i> 156(11):1070-1077.		
195.	Le Bourdonnec, B. et al. (2000). "Synthesis and Pharmacological Evaluation of New Pyrazolidine-3,5-diones as AT $_1$ Receptor Antagonists," <i>J. Med. Chem.</i> 43:2685-2697.		
196.	Le Bourdonnec, B. et al. (2002). "Comparison of 3D Structures and AT $_1$ Binding Properties of Pyrazolidine-3,5-diones and Tetrahydropyridazine-3,6-diones with Parent Antihypertensive Drug Irbesartan," <i>J. Med. Chem.</i> 45:4794-4798.		
197.	Lin, H.S. et al. (1992). "Nonpeptide Angiotensin II Receptor Antagonists: Synthetic and Computational Chemistry of N-[[4-(2H-Tetrazol-5-yl)-1-Cycloalken-1-yl]Phenyl]Methyl]Imidazole Derivatives and Their In Vitro Activity," <i>J. Med. Chem.</i> 35:2658-2667.		
EXAMINER: <i>le- wledb</i>		DATE CONSIDERED: <i>1-21-03</i>	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/08 (2-92) pa- 820933		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Harrihar A. PERSHADSINGH	
		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned
		Mailing Date November 21, 2003	
198.	Maillard, M.P. et al. (2002). "Pharmacodynamics and Drug Action: Comparative Angiotensin II Receptor Blockade in Healthy Volunteers: The Importance of Dosing," <i>Clin. Pharmacol. Ther.</i> 71(1):68-76.		
199.	Mederski, W.W. K.R. et al. (1994). "Non-Peptide Angiotensin II Receptor Antagonists: Synthesis and Biological Activity of a Series of Novel 4,5-Dihydro-4-oxo-3H-imidazo(4,5-c)pyridine Derivatives," <i>J. Med. Chem.</i> 37:1632-1645.		
200.	Meigs, J.B. et al. (2003). "The Natural History of Progression From Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging," <i>Diabetes</i> 52:1475-1484		
201.	Miyajima, A. et al. (2002). "Angiotensin II Type I Antagonist Prevents Pulmonary Metastasis of Murine Renal Cancer by Inhibiting Tumor Angiogenesis," <i>Cancer Res.</i> 62:4176-4179.		
202.	Miyazaki, M. et al. (1999). "Angiotensin II Type I Receptor Antagonist, TCV-116, Prevents Neointima Formation in Injured Arteries in the Dog," <i>Jpn. J. Pharmacol.</i> 79:455-460.		
203.	Nelson, K.A. et al. (1994). "The Cancer Anorexia-Cachexia Syndrome," <i>Journal of Clinical Oncology</i> 12(1):213-225.		
204.	Norman, M.H. et al. (1995). "4-(Heteroarylthio)-2-biphenyltetrazoles as Nonpeptide Angiotensin II Antagonists," <i>J. Med. Chem.</i> 38:4670-4778.		
205.	Phillips, M.I. and Kagiya, S. (2002). "Angiotensin II As A Pro-Inflammatory Mediator," <i>Curr. Opin. Investig. Drugs</i> 3(4):569-577.		
206.	Sasaki, K. et al. (2002). "Evidence for the Importance of Angiotensin II Type 1 Receptor in Ischemia-Induced Angiogenesis," <i>J. Clin. Invest.</i> 109:603-611.		
207.	Schmidt, B. and Schieffer, B. (2003). "Angiotensin II AT1 Receptor Antagonists. Clinical Implications of Active Metabolites," <i>J. Med. Chem.</i> 46(12):2261-2270.		
208. ✓	Sharma, A.M. et al. (2002). "Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells," <i>Hypertension</i> 40:609-611.		
209.	Shiuchi, T. et al. (2002). "ACE Inhibitor Improves Insulin Resistance in Diabetic Mouse via Bradykinin and NO," <i>Hypertension</i> 40:329-334.		
210.	Silvestre, J.S. et al. (2002). "Antiangiogenic Effect of Angiotensin II Type 2 Receptor in Ischemia-Induced Angiogenesis in Mice Hindlimb," <i>Circ. Res.</i> 90:1072-1079.		
211.	Smith, K.L. and Tisdale, M.J. (1993). "Mechanism of Muscle Protein Degradation in Cancer Cachexia," <i>British Journal of Cancer</i> 68:314-318.		
212.	Tamarat, R. et al. (2002). "Angiotensin II Angiogenic Effect in Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways," <i>Lab. Invest.</i> 82(6):747-756.		
213.	Tanaka, Y. et al. (1989). "Antitumor Activity of Indomethacin in Mice Bearing Advanced Colon 26 Carcinoma Compared with Those with Early Transplants," <i>Cancer Research</i> 49:5935-5939.		
EXAMINER: <i>[Signature]</i>		DATE CONSIDERED: 1-21-05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/08 (2-92) pa- 820933		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449

Docket Number 421842000400

Application Number 10/627,372

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Harrihar A. PERSHADSINGH

Filing Date July 24, 2003

Group Art Unit Not Yet Assigned


Mailing Date November 21, 2003

- | | |
|------|--|
| 214. | Teuscher, A.U. and Weidmann, P.U. (1997). "Requirements for Antihypertensive Therapy in Diabetic Patients: Metabolic Aspects," <i>Journal of Hypertension</i> 15(Supp. 2):S67-S75. |
| 215. | Tham, D.M. et al. (2002). "Angiotensin II Is Associated With Activation of NF- κ B-Mediated Genes and Downregulation of PPARs," <i>Physiol. Genomics</i> 11:21-30. |
| 216. | Tomiyama, H. et al. (1994). "Kinins Contribute to the Improvement of Insulin Sensitivity During Treatment with Angiotensin Converting Enzyme Inhibitor," <i>Hypertension</i> 23:450-455. |
| 217. | Wang, N. et al. (2002). "Constitutive Activation of Peroxisome Proliferator-Activated Receptor- γ Suppresses Pro-Inflammatory Adhesion Molecules in Human Vascular Endothelial Cells," <i>J. Biol. Chem.</i> 277(37):34176-34181. |
| 218. | Yusuf, S. et al. (2001). "Ramipril and the Development of Diabetes," <i>JAMA</i> 286:1882-1885. |
| 219. | Zimmet, P. et al. (2001). "Global and Societal Implications of the Diabetes Epidemic," <i>Nature</i> 414:782-787. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) 	Docket Number 421842000400	Application Number 10/627,372
	Applicant Harrihar A. PERSHADSINGH	
	Filing Date July 24, 2003	Group Art Unit 1632
	Mailing Date August 3, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

	Ref. No.	Title
1c	1.	Database Medline on STN (Columbus, OH, USA) Document No.: 22006210, Accession No.: 2002271257. Diep, Q. et al. (2002). "Structure, Edothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II- Infused Rats: Role Peroxisome Proliferator-Activated Receptor-Gamma," <i>Circulation</i> 105(9):2296-2302, abstract, 3 pages.
1c	2.	Database HCAPLUS on STN (Columbus, OH, USA) Document No.: 133:41183, Accession No.: 2000:195273. Vamecq, J. et al. (2000). "Peroxisome Proliferator-Activated Receptors (PPARs) and Their Implications in Diseases," <i>Current Opinion in Endocrinology & Diabetes</i> 7(1):8-18, abstract, 1 page.
1c	3.	International Search Report mailed on June 18, 2004, for PCT patent application no. PCT/US03/24881 filed on August 8, 2003, 5 pages.

EXAMINER:

4c. Waddell

DATE CONSIDERED:

1-21-05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.